Q-omics provides the consensus-scored ACOD1 profile across patient tissues and cancer cell-line models. ACOD1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ACOD1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ACOD1 RNA expression shows 11,449 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where ACOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACOD1 survival associations across molecular data types. ACOD1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACOD1 RNA expression–survival associations across cancer types. High ACOD1 expression shows unfavorable associations in KIRP, KIRC, THYM and LGG, but favorable associations in SKCM and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ACOD1 RNA expression.
This table summarizes ACOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACOD1 shows lower tumor expression in LUSC and higher tumor expression in HNSC, COAD, STAD, BRCA and READ. The HNSC box plot shows higher ACOD1 RNA expression in tumor versus normal tissue (log2 FC = +0.148, t-test p < 0.001).
This table shows molecular features associated with ACOD1 in patient tissues and cancer cell lines. In patient samples, ACOD1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ACOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
